TD Cowen Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220

نيوروكرين بيوساينسز

Neurocrine Biosciences, Inc.

NBIX

0.00

TD Cowen analyst Phil Nadeau maintains Neurocrine Biosciences (NASDAQ: NBIX) with a Buy and raises the price target from $200 to $220.